BrandMemo | manage and share brands you love  Pharmamedix su Facebook  Pharmamedix su Twitter
 Home | News | About us | Comitato scientifico | Iscriviti | Utenti | Etica | Contenuti | Guida | Faq | Stage | Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ziprasidone

Zeldox, Ziprasidone

Bibliografia - Quali fonti bibliografiche per Ziprasidone?


         
  1. Agenzia Italiana del Farmaco – AIFA, Zeldox – Riassunto caratteristiche di Prodotto, 2014 disponibile online https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/
  1. Bagnall A. et al., Cochrane Database Syst Rev., 2000, (4), CD001945.
  1. Boter H. et al., Schizophr. Res., 2009, 115 (2 3), 97.
  1. Caccia S., Clin. Pharmacokinet., 2000, 38 (5), 393.
  1. Caccia S., Expert. Opin. Drug Metab. Toxicol., 2011, 7 (7), 829.
  1. Caccia S., Pediatr. Drugs, 2013, 15 (3), 217.
  1. Caley C.F., Cooper C.K., Ann. Pharmacother., 2002, 36 (5),839.
  1. Carnahan R.M. et al., Pharmacotherapy, 2001, 21 (6), 717.
  1. Citrome L., J. Clin. Psychiatry, 2007, 68 (12), 1876.
  1. Citrome L., Adv. Ther., 2009, 26 (8), 739.
  1. Citrome L., Expert. Rev. Neurother., 2010,10 (7), 1031.
  1. Darwish M. et al., Clin. Drug Investig., 2014, 34 (10), 691.
  1. Davidson M. et al., Am. J. Psychiatry, 2009, 166 (6), 675.
  1. Elbe D., Carandang C.G., J. Can. Acad. Child Adolesc. Psychiatry, 2008 ,17 (4), 220.
  1. Food and Drug Administration – FDA, Warning Letter, 2002, 3 settembre disponibile online http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm164550.htm accesso luglio 2015
  1. Food and Drug Administration – FDA, Drug Safety Communication, 2014, 11 Dicembre.
  1. Findling R.L. et al., J. Child Adolesc. Psychopharmacol., 2013, 23 (8), 545.
  1. Findling R.L. et al., J. Child Adolesc. Psychopharmacol., 2013a, 23 (8), 531.
  1. Gardner D.M. et al., Ann. Gen. Psychiatry, 2013, 12 (1), 1.
  1. Gao K. et al., J. Clin. Psychopharmacol., 2008, 28 (2), 203.
  1. Gao K. et al., J. Clin. Psychopharmacol., 2013, 33 (3), 425.
  1. Greenberg W.M., Citrome L., CNS Drug Rev., 2007,13 (2), 137.
  1. Harrington C.A., English C., Pharmacotherapy, 2011, 31 (9), 840.
  1. Komossa K. et al., Cochrane Database Syst Rev., 2009, (4), CD006627.
  1. Leucht S. et al., 2009, 373 (9657), 31.
  1. Lieberman J.A. et al., NEJM, 2005, 353 (12), 1209.
  1. Loebel A.D. et al., J. Clin. Psychiatry, 2007, 68 (9), 1333.
  1. Mandrioli R. et al., Expert. Opin. Drug Metab. Toxicol., 2015, 11 1), 149.
  1. Manschreck T.C., Boshes R.A., Harv. Rev. Psychiatry, 2007, 15 (5), 245.
  1. Musil R. et al., Expert. Opin. Drug Saf., 2015, 14 (1), 73.
  1. Nemeroff C.B. et al., CNS Spectr., 2005, 10 (11 Suppl. 17), 1.
  1. Obach R.S., Walsky R.L., J. Clin. Psychopharmacol., 2005, 25 (6), 605.
  1. Preskorn S.H., Clin. Pharmacokinet., 2005, 44 (11), 1117.
  1. Sacchetti E. et al., Expert. Rev. Clin. Pharmacol., 2011, 4 (2), 163.
  1. Stahl S.M., Shayegan D.K., J. Clin. Psychiatry, 2003, 64 Suppl 19, 6.
  1. Stip E. et al., Clin. Ther., 2011, 33 (12), 1853.
  1. Strom B.L., Am. J. Psychiatry, 2011, 168 (2), 193.
  1. Vieta E. et al., J. Psychopharmcol., 2010, 24 (4), 547.
  1. Ziprasidone mesylate for injection. Material Safety Data Sheet, Pfizer 2010 disponibile on line http://www.pfizer.com/sites/default/files/products/material_safety_data/Ziprasidone_mesylate_Injection_28-Feb-2015.pdf Accesso marzo 2015.
  1. Ziprasidone. Monografia di Prodotto, 2009 Wolters Kluwer Health disponibile online http://www.pfizer.it/cont/pfizer-italia-materiali-prodotti/0906/2500/monografia-4560all1.pdf Accesso marzo 2015